Skip to main content

Colleen Niswender Archives

Drug discovery efforts may lead to new Rett syndrome treatments

Aug. 24, 2017—Vanderbilt University research-ers have relieved symptoms of Rett syndrome in a mouse model with a small molecule that works like the dimmer switch in an electrical circuit.

Read more


Vanderbilt begins Phase 1 trials of new Alzheimer’s drug

Aug. 7, 2017—Developed at Vanderbilt, VU319 is designed to precisely target a specific neuron receptor associated with cognitive function while avoiding potentially dangerous side effects.

Read more


VUMC’s Rett Syndrome Clinic lands national recognition

Nov. 17, 2016—Vanderbilt’s Rett Syndrome Clinic has been named a Rett Syndrome Clinical Research Center of Excellence by Rettsyndrome.org.

Read more


Study reveals possible ‘dimmer switch’ drug for Rett syndrome

Mar. 3, 2016—Researchers at Vanderbilt University Medical Center have relieved symptoms in a mouse model of Rett syndrome with a drug-like compound that works like the dimmer switch in an electrical circuit.

Read more


Autism Speaks grant boosts Rett syndrome research

Jan. 23, 2014—Colleen Niswender, Ph.D., research associate professor of Pharmacology, has received a three-year, $450,000 grant from the autism science and advocacy organization Autism Speaks to support studies investigating a possible new treatment for Rett syndrome.

Read more


Drug-like molecules aimed at improving treatment of Parkinson’s

Sep. 30, 2011—Drug-like molecules described by Vanderbilt researchers could lead to Parkinson's treatments with fewer side effects.

Read more


New drug-like molecules could improve schizophrenia treatment

Sep. 22, 2011—The discovery of new compounds that work in a fundamentally different way than those in existing schizophrenia medications may allow for more normal function of brain cells involved in schizophrenia.

Read more


Milestone in development of new treatment for ‘fragile X’

Sep. 15, 2011—Researchers at Vanderbilt University Medical Center, in collaboration with Seaside Therapeutics in Cambridge, Mass., have achieved a milestone in the development of a potential new treatment for fragile X syndrome, the most common genetic cause of autism.

Read more


Neuroscience drug discovery center opens at Vanderbilt

Mar. 11, 2011—Vanderbilt University Medical Center has established a new Center for Neuroscience Drug Discovery to accelerate research that may lead to new treatments for Parkinson's disease, schizophrenia and other disorders of the brain.

Read more


Upcoming Events

22 November
10:00 AM

29 November
10:00 AM

06 December
10:00 AM

13 December
10:00 AM

MORE EVENTS »